Tocilizumab in the management of Neuromyelitis Optica Spectrum Disorder: A Narrative Review of Literature and Critical Appraisal

Salman Mansoor; Samar Iltaf Mairajuddin; Saqib Gul

doi:10.56310/pjns.v19i03.235

Salman Mansoor Lister Hospital, East and North Hertfordshire NHS Trust
Samar Iltaf Mairajuddin Rashid Hospital, Dubai
Saqib Gul Hamdard College of Medicine and Dentistry, Hamdard University, Karachi

DOI: https://doi.org/10.56310/pjns.v19i03.235

Keywords: Neuromyelitis Optica Spectrum Disorder, Tocilizumab, IL-6 receptor, CNS Demyelinating diseases

Abstract

Background:

This review discusses tocilizumab, a monoclonal antibody, as a promising therapeutic option for Neuromyelitis optica (NMO) spectrum disorders. NMO is characterized as an autoimmune disorder that is rare. It affects the eyes and the spinal cord. By binding to the IL-6 receptor, tocilizumab reduces inflammatory cytokines and inhibits the immune response that leads to NMO.

Methodology:

For this article, a comprehensive search of the relevant literature was conducted using electronic databases namely PubMed, Cochrane Library, and Embase, from inception till August 2021.

Results:

Clinical trials that were included in this literature review showed promising results that tocilizumab reduces disease activity, and relapses, and improves clinical outcomes.

Conclusion:

In conclusion, tocilizumab represents a significant advance in treating NMO, but more studies might be needed to determine its long-term safety and the best way to use it for treating NMO spectrum disorders. However, the optimal dosing regimen and long-term safety of tocilizumab are yet to be determined.